← Back to Search

Topical Gel

VB-1953 topical gel - 2% BID for Acne

Phase 2
Waitlist Available
Research Sponsored by Vyome Therapeutics Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights

Summary

A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Dose-ranging Study in the Treatment of Acne Vulgaris,

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Inflammatory lesion counts
Secondary outcome measures
Investigator's Global Assessment of Inflammatory Acne (IGA) score
Percent change in inflammatory lesion counts

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: VB-1953 topical gel - 2% QDExperimental Treatment1 Intervention
VB-1953 topical gel - 2% QD
Group II: VB-1953 topical gel - 2% BIDExperimental Treatment1 Intervention
VB-1953 topical gel - 2% BID
Group III: VB-1953 VehiclePlacebo Group1 Intervention
VB-1953 topical gel- 0% (Vehicle) BID
Group IV: VB-1953 topical gel- 0% (Vehicle) QDPlacebo Group1 Intervention
VB-1953 topical gel- 0% (Vehicle) QD

Find a Location

Who is running the clinical trial?

Vyome Therapeutics Inc.Lead Sponsor
Dr. Shilpi JainStudy DirectorVyome Therapeutics Inc.
~77 spots leftby Jul 2025